Saturday 17 October 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
Vir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024. In the quarter to June 2026, revenue grew 19,582.5%, EPS grew 160.0% and free cash flow grew 200.5%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
9.96
0.51
−4.87%
Follow VIR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
47.05 | 12.18 | 20.16 | 5.64 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.73) | (32.28) | (9.97) | 13.86 | |
P/B ratio |
1.00 | 1.09 | 1.62 | 1.74 | |
Price to Tangible BV |
1.03 | 1.13 | 1.68 | 1.78 | |
EV/Sales |
16.88 | 5.34 | 12.86 | 3.87 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.63) | (0.94) | (1.89) | (5.80) | |
EV/FCF |
(0.62) | (0.92) | (1.87) | (5.77) | |
Quick Ratio |
6.76 | 5.05 | 6.50 | 5.63 | |
Current Ratio |
7.25 | 5.54 | 7.11 | 6.04 | |
Net Debt/EBITDA |
3.01 | 10.79 | 3.70 | (6.98) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.06 | 0.06 | 0.25 | |
Operating CF/Net income |
1.03 | 0.60 | 1.05 | 1.54 | |
Capex/Depreciation |
(0.06) | (0.10) | (0.12) | (0.01) | |
Research and Development Expense of Revenue |
63,109.58% | 137.89% | (375,593.10%) | 56.62% | |
Selling, General and Administrative Expense of Revenue |
9,262.92% | 36.86% | (80,479.31%) | 12.64% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
4,731.67% | 17.49% | (41,679.31%) | 5.19% | |
Graham Net Nets |
0.41 | 0.33 | 0.23 | 0.20 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(63.22%) | (52.40%) | (34.93%) | (18.16%) | |
Free Cash Flow Yield |
(57.63%) | (47.45%) | (34.06%) | (11.92%) | |
Revenue per Share |
0.00 | 0.46 | 0.00 | 1.42 | |
Operating CF per Share |
(1.21) | (0.19) | (0.90) | 0.74 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.21) | (0.19) | (0.90) | 0.74 | |
Cash per Share |
3.66 | 3.39 | 3.25 | 3.19 | |
Shareholders Equity per Share |
5.73 | 5.52 | 5.52 | 5.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.73 | 5.52 | 5.52 | 5.86 | |
Free Cash Flow |
(167.85) | (26.33) | (132.78) | 123.29 | |
Working Capital |
470.46 | 421.27 | 449.43 | 478.78 | |
Capital Expenditures |
(0.28) | (0.46) | (0.39) | (0.03) | |
Net Current Asset Value |
322.33 | 276.53 | 310.17 | 341.43 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
1.17 | 0.01 | (13.45) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
7.08 | 7.44 | 4.59 | 14.99 | |
Average Assets |
1,258.90 | 1,200.82 | 1,166.66 | 1,203.67 | |
Average Common Equity |
1,018.41 | 957.83 | 928.29 | 964.98 |
Columns are period end dates